Overview

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Status:
RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous injection in healthy subjects and patients with ITP, and to further explore the initial efficacy of STSA-1301 subcutaneous injection in patients with ITP
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu BioJeTay Biotechnology Co., Ltd.